Clinical trials: Checkpoint Inhibitor
Non Small Cell Lung Cancer, Immune Checkpoint Inhibitors (ICIs)
ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
The CR1STAL-Adaptive study is a randomized, open-label, phase II multicenter interventional trial designed to evaluate the safety and efficacy of Ivonescimab (PD-1/VEGF bispecific antibody) combined with docetaxel versus standard…
- Trial name
- NCT06951646
- Testing
- Ivonescimab, Docetaxel, Standard Treatment group
- Where
- 20 sites in China
- Volunteers
- 70 people
- Sponsor
- Second Xiangya Hospital of Central South University
Checkpoint Inhibitor-related Pneumonitis
Diagnostic Biomarkers for Checkpoint Inhibitor-related Pneumonitis
Checkpoint inhibitor-related pneumonitis (CIP) is a common fatal immune-related adverse events of PD-1/PD-L1 inhibitors. Early diagnosis of CIP is crucial for timely intervention and improved prognosis; however, the absence of…
- Trial name
- NCT07340892
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhou Chengzhi
HCC, Adjuvant Therapy
Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma
Early hepatocellular carcinoma (HCC) recurrence (driven by residual tumors) and late recurrence (driven by de novo tumors) exhibit distinct biological behaviors, suggesting differential therapeutic vulnerabilities.
- Conditions
- HCC, Adjuvant Therapy, Recurrence, Immune Checkpoint Inhibitor
- Trial name
- NCT07379489
- Testing
- PD-1 Inhibitors
- Volunteers
- 300 people
- Sponsor
- Tongji Hospital
Non Small Cell Lung Cancer, Breast Cancer
Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.
This is an observational clinical trial, aiming to investigate whether the ctDNA dynamics could predict early response to ICIs in patients with advanced-stage cancer.
- Conditions
- Non Small Cell Lung Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer
- Trial name
- PTC-IMPACT (NCT06227728)
- Where
- 2 sites in Vietnam
- Volunteers
- 50 people
- Sponsor
- Gene Solutions
Immune Checkpoint Inhibitor-Related Diarrhea and Colitis
Etrasimod for Immune Checkpoint Inhibitor Diarrhea and Colitis
This is a randomized, double-blind, placebo-controlled, two-arm phase 2 study of etrasimod plus corticosteroids versus placebo plus corticosteroids for the treatment of IMDC CTCAE v5.0 grade ≥ 2 due to ICI therapy alone…
- Trial name
- NCT06521762
- Testing
- Etrasimod, Corticosteroids
- Where
- United States
- Sponsor
- Yale University
Non Small Cell Lung Cancer, Immune Checkpoint Inhibitors
Impact of Pretreatment Emotional Distress on Survival and the Predictive Role of Peripheral Biomarkers in Immunotherapy Response Among Gastroesophageal and Lung Cancer Patients
This is the prospective, observational cohort study to explore the impact of pretreatment emotional distress on survival and the predictive role of peripheral blood metabolic and inflammatory markers in immunotherapy response…
- Conditions
- Non Small Cell Lung Cancer, Immune Checkpoint Inhibitors, Inflammation, Cancer, Treatment-Related
- Trial name
- NCT06629714
- Testing
- Exposure: emotional distress status
- Where
- China
- Volunteers
- 196 people
- Sponsor
- Anhui Medical University
Skin Toxicity in Patients on Checkpoint Inhibitors
"Evaluation of a Non-Pharmacological Skin Care Intervention for the Prevention and Treatment of Skin Toxicities Caused by Immunotherapy in Cancer Patients"
Due to recent approvals, a significant number of adult cancer patients are undergoing treatment with checkpoint inhibitor antibodies.
- Trial name
- NCT07337486
- Testing
- Shea Butter and Niacinamide, Argan Oil and Coconut Butter
- Where
- Spain
- Volunteers
- 130 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Immune Checkpoint Inhibitor-Related Myocarditis
Monitoring and Rehabilitation for ICIACI Rehabilitation：A Cohort Study
Immune checkpoint inhibitor-associated cardiac injury (ICIACI) is a low-incidence but highly fatal adverse event. A significant knowledge gap exists regarding the disease characteristics and recovery status of patients during the…
- Trial name
- NCT07278817
- Volunteers
- 340 people
- Sponsor
- China-Japan Friendship Hospital
Immune Checkpoint Inhibitors Related Myocarditis
ICIAM Rehabilitation Program Study: A Randomized Controlled Trial
Immunotherapy has become a cornerstone in oncology; however, managing its associated adverse events poses a significant clinical challenge.
- Trial name
- NCT07280429
- Testing
- rehabilitation protocol
- Volunteers
- 60 people
- Sponsor
- China-Japan Friendship Hospital
Solid Cancer, Lymphopenia
PRaG-1 Plus PRaG Therapy in Advanced Solid Tumors: A Prospective Clinical Trial (PRaG 10.0)
The goal of this clinical trial is to learn if a combination treatment using PRaG-1 Cordycepin Tablets with radiation therapy, immune-boosting injections, and immunotherapy drugs can help patients with advanced solid tumors.
- Conditions
- Solid Cancer, Lymphopenia, Radiotherapy, Immune Checkpoint Inhibitor
- Trial name
- NCT07267234
- Testing
- PD -1/PD-L1 monoclonal antibody
- Volunteers
- 65 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Immune Checkpoint Inhibitor-Related Colitis
Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial
The goal of this clinical trial is to compare the effectiveness and safety of Vedolizumab with a short course of steroids compared to standard course of steroids for the treatment of immune checkpoint inhibitor colitis (ICI…
- Trial name
- EVITA (NCT06841705)
- Testing
- Vedolizumab 300 MG Injection [Entyvio], Prednisone (and methylprednisolone), Prednisone Taper
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Shilpa Grover, MD, MPH
Immune Checkpoint Inhibitors (ICI)-Related Dermatitis
JAK Inhibitors for Solid Malignant Tumor Patients With Immune Checkpoint Inhibitors-related Dermatitis: A Open-lable, Single Arm, Phase IIa Trial
Currently, the principal strategy for immune checkpoint inhibitors (ICI)-related dermatitis include systemic use of corticosteroids, which can impair the efficacy of preceding ICIs treatment.
- Trial name
- NCT06715982
- Testing
- JAK Inhibitor
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Shixiu Wu
Cancer Treated With Immune-checkpoint Inhibitors
Immune-checkpoint Inhibitors and Surrogate Endpoints in Cancer Trials (SURROGATE-ICI)
Time to next treatment or death (TNT-D) may be a patient-relevant endpoint in patients treated with immune checkpoint inhibitors. This study investigate
- Trial name
- SURROGATE-ICI (NCT03963518)
- Testing
- nivolumab monotherapy, nivolumab plus ipilimumab
- Where
- France
- Volunteers
- 631 people
- Sponsor
- Institut Bergonié
Colonic Neoplasms, Neoadjuvant Therapy
Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer
This study aims to elucidate the effects of neoadjuvant Tislelizumab combined with chemotherapy in locally advanced Microsatellite Stable (MSS) colon cancer.
- Conditions
- Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors
- Trial name
- NCT06124378
- Testing
- Tislelizumab, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Pain Management, Immune Checkpoint Inhibitor
Study on the Relationship Between Opioid Drugs and the Therapeutic Efficacy of Immunotherapy
Relationship between pain and the efficacy of immunotherapy: Does the degree of pain control affect the therapeutic efficacy of ICIs? Does the use of opioid drugs independently affect the efficacy of immunotherapy?
- Conditions
- Pain Management, Immune Checkpoint Inhibitor, Opioid
- Trial name
- NCT07188857
- Volunteers
- 100 people
- Sponsor
- Hubei Cancer Hospital
Hepatocellular Carcinoma (HCC), Radiotherapy, Adjuvant
Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC
This study is an open-label, randomized controlled, multicenter, phase III clinical trial
- Conditions
- Hepatocellular Carcinoma (HCC), Radiotherapy, Adjuvant, Immune Checkpoint Inhibitor, TACE
- Trial name
- NCT07186621
- Testing
- Sintilimab, radiotherapy, TACE
- Where
- China
- Volunteers
- 286 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Biliary Tract Cancer, Disitamab Vedotin
Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer
This trial is a single-arm exploratory phase II clinical study initiated by the investigator. Subjects who met the research criteria were screened and enrolled to receive the treatment regimen of disitamab vedotin combined with…
- Conditions
- Biliary Tract Cancer, Disitamab Vedotin, Lenvatinib, Immune Checkpoint Inhibitors
- Trial name
- NCT07159217
- Testing
- Disitamab Vedotin, Lenvatinib, Pembrolizumab
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Peking Union Medical College Hospital
Renal Cell Carcinoma, Radiotherapy
A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy
The objective of this single-center clinical study was to evaluate the disease control rate(DCR) and safety of multimodal radiotherapy in the treatment of patients with renal cell carcinoma (RCC) progressed after prior…
- Conditions
- Renal Cell Carcinoma, Radiotherapy, Immune Checkpoint Inhibitor
- Trial name
- NCT06255223
- Testing
- High-dose Radiotherapy (HDRT), Low-dose Radiotherapy (LDRT), Anti-PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Jinling Hospital, China
Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization
The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma
We adopted the prospective cohort study to compare the safety and efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody in the treatment of advanced unresectable liver…
- Conditions
- Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization, Tyrosine Kinase Inhibitor, Immune Checkpoint Blockade
- Trial name
- NCT04997850
- Testing
- lenvatinib + sindilimab/carrelizumab, TACE
- Where
- China
- Volunteers
- 142 people
- Sponsor
- Xinrui Zhu，MD
HCC - Hepatocellular Carcinoma, Psychological Distress
The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study
The goal of this observational study is to learn if emotional distress affects how well liver cancer treatment works in people receiving immunotherapy. Emotional distress means feeling anxious or depressed.
- Conditions
- HCC - Hepatocellular Carcinoma, Psychological Distress, Immune Checkpoint Inhibitors (ICIs), Cancer, Treatment-Related
- Trial name
- SOLACE (NCT07141056)
- Testing
- Psychological Stress Status
- Where
- 5 sites in China
- Volunteers
- 700 people
- Sponsor
- Guilin Medical University, China